B7-33 (6mg) Peptide – Research Overview

B7-33 (6mg) is a synthetic peptide analog derived from the B-chain of the naturally occurring hormone human relaxin-2 (H2 relaxin). Unlike full-length relaxin, B7-33 is a truncated peptide engineered to selectively activate specific relaxin signaling pathways while minimizing off-target interactions. At Core Peptide, B7-33 (6mg) is supplied exclusively for research and laboratory use within the United States.

Relaxin peptides have been widely studied for their roles in extracellular matrix remodeling, vascular function, inflammatory signaling, and fibrosis regulation. B7-33 has emerged as a focused research tool due to its ability to engage the RXFP1 receptor without triggering the full spectrum of relaxin-associated hormonal effects.

Learn more about our research-grade peptide standards:
https://corepeptide.us/pages/quality-assurance

What Is B7-33?

B7-33 is a shortened peptide fragment derived from the B-chain of human relaxin-2. Traditional relaxin peptides interact with RXFP1 receptors to influence connective tissue turnover, vascular tone, and inflammatory processes. However, full-length relaxin also activates secondary signaling cascades that may complicate experimental interpretation.

B7-33 (6mg) was designed to:

• Retain RXFP1 receptor activation

• Reduce hormonal and reproductive signaling

• Provide pathway-selective research outcomes

This selective signaling profile has made the B7-33 peptide particularly valuable in experimental models focused on fibrosis, cardiovascular remodeling, and chronic inflammation.

RXFP1 Receptor Signaling and B7-33

The RXFP1 receptor is a G protein–coupled receptor expressed in:

• Cardiovascular tissues

• Fibroblasts

• Renal tissue

• Pulmonary and hepatic cells

Activation of RXFP1 has been linked to:

• Regulation of collagen synthesis

• Modulation of inflammatory cytokines

• Nitric oxide (NO) signaling pathways

• Tissue compliance and remodeling

Studies suggest that B7-33 (6mg) may activate RXFP1-mediated pathways such as cAMP signaling and ERK phosphorylation, while avoiding excessive activation of pathways associated with edema or systemic hormonal effects seen with full-length relaxin.

https://pubmed.ncbi.nlm.nih.gov/25080414/

B7-33 and Fibrosis Research

One of the primary research interests surrounding B7-33 peptide is its potential role in anti-fibrotic signaling. Fibrosis is characterized by excessive collagen deposition and extracellular matrix stiffening, commonly observed in:

• Cardiac remodeling

• Pulmonary fibrosis

• Renal fibrosis

• Liver fibrosis

Preclinical research models suggest that B7-33 may:

• Downregulate collagen I and III expression

• Reduce fibroblast activation

• Modulate transforming growth factor-β (TGF-β) signaling

By selectively activating RXFP1 pathways, B7-33 (6mg) provides researchers with a tool to study fibrosis attenuation without introducing broader endocrine variables.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553474/

Cardiovascular Research Applications

Relaxin signaling has long been associated with vascular compliance and endothelial function. In cardiovascular research models, B7-33 has been studied for its potential involvement in:

• Vasodilation signaling

• Reduction of vascular stiffness

• Nitric oxide bioavailability

• Inhibition of maladaptive cardiac remodeling

Unlike full-length relaxin, B7-33 (6mg) may offer a more controlled approach for studying RXFP1-mediated cardiovascular pathways, particularly in heart failure and hypertensive research models.

Inflammatory Pathway Modulation

Chronic inflammation often accompanies fibrosis and cardiovascular disease. Research indicates that RXFP1 activation may influence inflammatory mediator release, including:

• Tumor necrosis factor-α (TNF-α)

• Interleukins (IL-1β, IL-6)

• Macrophage activation states

B7-33 peptide has been investigated as a means to observe how selective relaxin signaling may alter inflammatory responses without widespread immune suppression. This makes B7-33 (6mg) relevant in immunological and chronic disease research environments.

Chemical and Structural Information

• Peptide Class: Relaxin-2 B-chain analog

• Receptor Target: RXFP1

• Form: Lyophilized research peptide

• Quantity: 6mg

B7-33 lacks the A-chain present in native relaxin, which contributes to its signaling selectivity and experimental precision.

B7-33 (6mg) for Research in the United States

Core Peptide supplies B7-33 (6mg) to research laboratories across the United States. All peptides are:

• Manufactured to research-grade purity standards

• Independently tested for quality and consistency

• Intended strictly for laboratory and scientific research

 Explore related research peptides:
https://corepeptide.us 

Conclusion

B7-33 (6mg) represents a refined research peptide engineered to selectively activate RXFP1 receptor signaling while minimizing off-target hormonal effects. Its growing relevance in fibrosis, cardiovascular, and inflammatory research makes it a valuable addition to modern peptide-based studies. For U.S.-based laboratories seeking reliable sourcing and consistent quality, Core Peptide remains a trusted provider of research-only peptides.